Skip to main content

Table 1 Baseline characteristics of patients according to treatment groups: clinical, immunovirological and body composition data, biological markers

From: Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study

Parameter + PI (n = 16) + NNRTI (n = 19) p Normal range
Age, y 42.3 (14.5)* 39.7 (11.9)* 0.57  
Sex ratio (M,%) 62.5 63.2 0.96  
Origin    0.96  
  European (%) 75.0 73.7
  African (%) 25.0 26.3
Current smokers (%) 0 31.6 0.03  
Duration of diagnosed infection, years 2.2 (2.9)* 1.6 (1.8)* 0.46  
CDC categories    0.31  
  A + B (%) 81.3 94.7
  C (%) 18.7 5.3
Viral load (log10/ml) 5.05 (0.85)* 5.04 (0.55)* 0.97  
CD4 lymphocytes/ml 240 (153)* 240 (131)* 0.90  
BMI, kg/m2 23.8 (3.6)* 24.0 (3.6)* 0.84  
Body Lean Mass, kg 46.3 (8.8)* 49.4 (10.3)* 0.35  
Body Fat Mass, kg 18.4 (8.9)* 19.4 (10.9)* 0.79  
Fat Mass ratio 0.97 0.97 0.99  
  In men 1.05 (0.16)* 1.03 (0.14)* 0.81 ≤ 1.5
  In women 0.85 (0.10)* 0.87 (0.14)* 0.74 ≤ 1.2
BMD L2-L4 (g/cm2) 1.233 1.249 0.82  
Cholesterol, g/l 1.88 (0.45)* 1.61 (0.34)* 0.05 1.5 – 2.2
HDL-cholesterol, g/l 0.44 (0.08)* 0.38 (0.10)* 0.10 > 0.4
Triglycerides, g/l 1.14 (0.58)* 0.99 (0.48)* 0.46 0.5 – 1.5
Glucose, g/l 0.84 (0.08)* 0.83 (0.09)* 0.79 0.72 - .1.05
Total alkaline phosphatase, U/l 168 (37)* 173 (49)* 0.73 100 – 280
Bone alkaline phosphatase, μg/l 8.1 (3.2)* 8.3 (2.6)* 0.88 5 – 20
β-Cross-laps, μg/l 353 (186)* 302 (161)* 0.39 160 – 440
25-OH-vitamine D3, μg/l 20.7 (8.2)* 19.4 (12.0)* 0.71 22 – 45
1,25-di-OH-vitaminne D3, ng/l 49.1 (18.7)* 49.3 (18.4)* 0.97 25 – 60
Parathormone, ng/l 34.1 (12.9)* 35.1 (13.3)* 0.83 10 - 65
Cockroft (ml/min) 83.9 (21.9)* 102.3 (17.3)* 0.01  
  1. * mean value (standard deviation).